Background: A resurgence of pertussis cases among both vaccinated and unvaccinated people raises questions about vaccine effectiveness over time. Our objective was to study the effectiveness of the pertussis vaccine and characterize the effect of waning immunity and whole-cell vaccine priming.
W
hooping cough, or pertussis, is a highly contagious respiratory infection that has been inadequately controlled compared with other vaccine-preventable diseases. The incidence of pertussis in Canada decreased from 156 cases per 100 000 population during the prevaccination era to a historic low of 2.0 per 100 000 in 2011, increased to 13.9 in 2012, and then decreased to 3.6 in 2013. 1 Ontario, Canada's most populous province with a population of 13.5 million in 2013, experienced a localized outbreak in 2012. This outbreak started in a largely unvaccinated religious community and disproportionately affected infants, but then spread to the general population and mostly involved adolescents. 2 Consequently, the outbreak raised questions about product-specific vaccine effectiveness and waning immunity.
Pertussis vaccines have been available in Ontario for more than 70 years. In 1997, owing to concerns about safety and effectiveness, acellular pertussis vaccine replaced the whole-cell product that had been in use since 1984. [3] [4] [5] In Ontario, only the 5-component acellular vaccine (containing pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3) has been available for infants and toddlers. Vaccination against pertussis is recommended at 2, 4, 6 and 18 months, and at 4-6 years. In 2003, an adolescent dose at 14-16 years was introduced, and in 2011, a program was started for singledose adult vaccination against pertussis. 6 Other jurisdictions in Canada, the United States and Australia have reported lower effectiveness with the acellular product and rapidly waning immunity. [7] [8] [9] [10] [11] Canada has a unique history of using a whole-cell vaccine with lower effectiveness, and also has different secular trends in pertussis incidence and vaccination coverage, necessitating local evaluation of the effectiveness of the pertussis vaccine to inform vaccination policy. Our objective was to study the effectiveness of the pertussis vaccine in Ontario while characterizing the effect of waning immunity and whole-cell vaccine priming.
Methods

Study population, setting and design
We linked Bordetella pertussis polymerase chain reaction (PCR) test results from Public Health Ontario Laboratory Services to population-based provincial health administrative data (linkage success rate 96%). To assess the effectiveness of the pertussis vaccine, we used the test-negative design, a type of nested case-control study often used to assess the effectiveness of the influenza vaccine because it generates unbiased estimates comparable to those from randomized controlled trials (RCTs).
12-14
The study population comprised Ontario residents born between Apr. 1, 1992, and Jan. 1, 2013. We excluded records with invalid postal codes, children younger than 3 months and individuals who were registered for coverage in Ontario's universal health care system at 6 months of age or older to account for those who may have received their primary vaccination series elsewhere. We excluded vaccinations given within 14 days of testing owing to insufficient time to mount an adequate immunologic response.
Data sources and definitions
Laboratory data
Public Health Ontario's laboratory database contains results for more than 95% of Ontario's diagnostic testing for pertussis; testing is available to all Ontario physicians. The laboratory methods have been previously described. [15] [16] [17] Briefly, until May 28, 2012, primers targeting the insertion sequence IS481 were used to detect B. pertussis. Following this date, primers targeting a 50-base pair segment of the recA gene were also included to distinguish B. pertussis from Bordetella holmesii. Evaluation of the new assay showed that less than 1% of previously tested pertussis-positive specimens were B. holmesii. 17 Polymerase chain reaction tests were considered positive for pertussis at cycle threshold values of 35 or less, and indeterminate at 36-40. Specimens with no amplification signal were considered negative. These values were constant throughout the study period. 
Pertussis vaccination
The database of the Ontario Health Insurance Plan (OHIP) contains physician-billing information on virtually all Ontario residents starting Jan. 1, 1992, except for new residents within their first 3 months of residency. 18 We classified vaccination status as up to date for age, partially vaccinated or unvaccinated. The number of age-appropriate doses is 1 dose at 3 months, 2 doses at 5 months, 3 doses at 7 months, 4 doses at 19 months, 5 doses at 7 years and 6 doses at 17 years, based on Ontario's immunization schedule. 6 We defined a priming series as the first 3 doses of vaccine received. Vaccines in Ontario are purchased centrally for the entire province. The Connaught whole-cell vaccine was available between 1992 and 1996, and only acellular vaccine in 1998 and later. Vaccines administered in 1997 were used in a sensitivity analysis because of uncertainty regarding the overlap of products used that year. Ontario's immunization codes have been previously validated in infants. 19 We performed a further validation analysis of pertussis codes for this study (Appendix 1, available at www.cmaj.ca/ lookup/suppl/doi:10.1503/cmaj.160193/-/DC1).
Covariates
We used Ontario's Registered Persons Database, which contains demographic information on all individuals with a valid Ontario health card, 20 to obtain age, sex, socioeconomic status (approximated by neighbourhood income quintile) 21 and rural residence (community size < 10 000). We used the Canadian Institute for Health Information (CIHI) Discharge Abstract Database to identify chronic conditions. 22 Health care use within the previous year (including physician visits, emergency department use and hospital admissions) was enumerated using OHIP, the CIHI National Ambulatory Care Reporting System and the Discharge Abstract Database, respectively. These data sets were linked using unique encoded identifiers and analyzed at the Institute for Clinical Evaluative Sciences.
Statistical analysis
The proportion of pertussis cases by time since last vaccination was evaluated using the Cochran-Armitage trend test. We used multivariable logistic regression models to estimate crude and adjusted odds ratios (ORs) for pertussis infection, assessing participants with up-to-date or partial vaccination compared with unvaccinated participants. We stratified the data by time since last vaccination: 15-364 days, 1-3 years, 4-7 years, and 8 or more years since last vaccination. These periods were selected in relation to age-based vaccination recommendations and based on expected waning of immunity from previous studies. 10, 23 The variables age, sex, any comorbidity, 22 income quintile, rural residence, ambulatory, emergency and inpatient health care use in the past 12 months were selected a priori for inclusion in the multivariable models. We calculated vaccine effectiveness as (1 -OR) × 100. 24 Waning immunity of the acellular pertussis vaccine was further assessed in those born in 1997 or later by estimating the odds of pertussis for each year following the last vaccine dose received, adjusted for the same covariates above, among those with up-to-date vaccination, those with either up-to-date or partial vaccination, and those who had received 5 or more previous doses of pertussis vaccine (i.e., older individuals who should have received the preschool diphtheria and tetanus toxoids and acellular pertussis [DTaP] or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis [Tdap] vaccine).
We evaluated the relative impact of priming with acellular versus whole-cell vaccine in those aged 10 years and older who had received 5 or more pertussis vaccinations. We constructed multivariable logistic regression models to estimate the odds of pertussis if the priming series used acellular vaccine only compared with whole-cell vaccine only, and compared with 1 or more doses of whole-cell vaccine.
We used the PROC LOGISTIC procedure (SAS 9.3) for all analyses. Type 1 error was set at 5% (p < 0.05). We evaluated all variables for multicollinearity through the variance inflation factor. Model fit was evaluated with the Hosmer-Lemeshow test.
Sensitivity analysis
Because of the potential nondifferential misclassification bias of vaccination status from physician billing claims, we performed a quantitative sensitivity analysis that examines the impact of the known sensitivity and specificity of the exposure variable on the estimate of vaccine effectiveness. 25 Details are in Appendix 2, available at www.cmaj.ca/lookup/suppl/doi:10.1503/ cmaj.160193/-/DC1. We evaluated the impact of an incomplete primary series by excluding infants younger than 7 months. We also analyzed indeterminate pertussis results, separating time periods (2009-2011 v. 2012-2013 ) and excluding cases from a localized outbreak.
Ethics approval
We received ethics approval from Public Health Ontario, Sunnybrook Health Sciences Centre and the University of Toronto.
Results
We linked 7560 individuals born after Apr. 1, 1992, with a pertussis PCR test result between Dec. 7, 2009, and Mar. 31, 2013. We excluded 1112 infants younger than 3 months, 361 people who registered for Ontario health insurance at age 6 months or older, and 220 people with indeterminate results. The final study population included 5867 participants (486 pertussis-positive cases and 5381 pertussis-negative controls).
Cases were older than controls by a mean of 2.7 years (Table 1) . Cases were more likely to reside in rural areas and to have been tested in 2012. Controls had higher rates of comorbidities and had accessed more health care in the previous 12 months.
Of the 486 cases, 193 (39.7%) had up-todate vaccination against pertussis according to our definition, 134 (27.6%) were partially vaccinated and 159 (32.7%) were unvaccinated. Among the 5381 controls, 3384 (62.9%) were up to date, 1212 (22.5%) were partially vaccinated and 785 (14.6%) were unvaccinated. Of the participants, 120 (24.7%) cases and 1121 (20.8%) controls had received 5 or more doses.
Unadjusted vaccine effectiveness declined over time by about 10% per year since last vaccination in those with up-to-date or partial vaccination (Figure 1) . Correspondingly, the proportion of positive cases increased by about 2% each year since last vaccination (p < 0.001, by the Cochran-Armitage trend test).
Compared with unvaccinated participants, the adjusted estimates of vaccine effectiveness for participants who had up-to-date vaccination, stratified by time since last vaccination, were 80% (95% CI 71% to 86%) at 15-364 days, 84% (95% CI 77% to 89%) at 1-3 years, 62% (95% CI 42% to 75%) at 4-7 years and 41% (95% CI 0% to 66%) at 8 or more years since last vaccination ( Table 2 ). The trend was similar when we compared the partially vaccinated group with the unvaccinated group.
Individuals who received only an acellular vaccine had significant waning of immunity. Compared with those who received at least 3 priming doses of whole-cell vaccine, individuals who received only acellular vaccine had an adjusted OR of 2.15 (95% CI 1.30 to 3.57). Compared with participants who received 1 or more whole-cell vaccinations, those who received acellular vaccine for their priming series had an adjusted OR of 1.82 (95% CI 1.18 to 2.82). The results from the sensitivity analysis evaluating participants who received a dose in 1997 assigned as either whole cell or acellular were similar (data not shown).
Sensitivity analysis
Accounting for nondifferential misclassification bias of vaccination status, vaccine effectiveness increased from 80%-85% to 95% or greater within 3 years since last vaccination. However, vaccine effectiveness was 63% after 4-7 years and declined to 22% (95% CI -70% to 73%) after 8 or more years (Table 2, Appendix 2). Excluding infants with an incomplete primary series, vaccine effectiveness increased within 1 year from last vaccination from 80% to 87%. Individuals tested in 2012-2013 were the main drivers of the waning immunity observed (Table 2) .
Interpretation
We observed high effectiveness of the pertussis vaccine within 3 years of vaccination, but with clear evidence of waning of immunity beyond 4 years and little-to-no protection beyond 7 years from last vaccination. The odds of pertussis increased by 27% each year that passed after receipt of an acellular vaccine. Individuals primed with acellular vaccine had a 2.2 times higher odds of disease than those primed with the previously used whole-cell vaccine.
Recent observational studies from the US have yielded some comparable results. 10, 11, [26] [27] [28] Our analysis, which is stratified by time since last vaccination and adjusted for age, suggests that the low estimates of vaccine effectiveness beyond 4 years from last vaccination are attributable to waning immunity. A recent metaanalysis identified an increased odds of pertussis of 33% for each year following the DTaP dose. 23 That meta-analysis supports our finding that beyond 7 years since the last vaccination there is minimal protective effect of the vaccine, despite some evidence showing persistent humoural immunity. 29 The findings of the current study are important because of its context. Our study population of Ontario residents received a 5-component acellular vaccine with consistently high coverage levels, had a history of a different whole-cell vaccine from the US and had no substantial population-wide resurgences of disease, yet our results showed similar rapid waning of immunity. Furthermore, our finding that the low-effectiveness whole-cell vaccine is still better for priming than the currently used acellular vaccine nearly 2 decades after the change in practice has profound implications for understanding the effectiveness of the pertussis vaccine. Ontario transitioned to acellular vaccines owing to concerns about safety and effectiveness of the whole-cell vaccine used in Canada. Observational data from Canada, Australia and the US have shown greater protection with whole-cell infant priming. [7] [8] [9] We were surprised to see a significant protective effect, given the estimated low effectiveness of this particular whole-cell vaccine of 49%-61%. [3] [4] [5] However, our results showed that receiving 1 or more doses of whole-cell vaccine as an infant provided significant protection from pertussis more than a decade later.
Immunization advisory committees in Canada and the US recommend a Tdap booster for adolescents and adults. However, uptake of these recommendations as measured by pertussis vaccine coverage in Ontario and Canada has been about 70% among adolescents and only 7% among adults. [30] [31] [32] [33] Given our data, combined with reports from others, 10, 11 it is unsurprising that we are witnessing a resurgence of pertussis in adolescents and adults. 2, 11 The presence of a large susceptible population puts young infants, in whom virtually all of the morbidity and mortality is observed, at risk of acquiring infection. 1 Our findings suggest the need to reconsider our strategy for pertussis vaccination. In Ontario, individuals currently aged 18 years and younger have received only acellular vaccines, creating a large susceptible population. Vaccination in pregnancy is recommended in the US and the United Kingdom, and is likely an effective strategy to reduce disease in infants. 34 We recommend that decisions to strengthen control of pertussis be informed by dynamic modelling to compare the relative costs and benefits of different strategies. Consideration should also be given to introducing whole-cell vaccine for infant priming given the observational data showing significant long-term protective effects combined with the discovery that many cases of encephalopathy, temporally associated with the diphtheria and tetanus toxoids and pertussis (DTP) vaccine, were not causally attributable to pertussis vaccines. 35, 36 A recent model evaluating a 1-dose whole-cell priming strategy suggests that this approach is highly cost-effective. 37 The benefit of additional boosters likely varies based on the cause of pertussis resurgence, which suggests that a better understanding of the current epidemiology of pertussis is critical for optimizing public policy. ¶The variable "any comorbidity" was excluded from these models owing to quasi-separation of data points.
Limitations
There is potential for false-negative results (cases being misclassified as controls) with the test-negative design, which would tend to underestimate vaccine effectiveness. However, test-positive cases are likely more severe than all pertussis cases in the population, 39 thereby potentially overestimating vaccine effectiveness. This design minimizes the bias related to health care-seeking behaviour and has been validated against RCT data for other infections such as influenza and respiratory syncytial virus.
14 In Ontario, pertussis vaccinations are administered predominately through physician offices. Nonetheless, some misclassification bias of vaccination status was observed. Our sensitivity analysis showed an underestimation of early vaccine effectiveness with a more dramatic waning of immunity over time. We incorporated all clinically relevant available covariates in the multivariable models to adjust for potential confounding; however, additional unmeasured confounders that could not be captured by administrative data are possible.
Conclusion
We identified good early vaccine effectiveness, which rapidly declined when time since last vaccination surpassed 4 years, in a population with relatively stable disease incidence. We also identified a significant protective effect from priming with a low-effectiveness whole-cell product. This study highlights the need to re-evaluate strategies for pertussis vaccination in Canada and to spur vaccine development.
